Cite
BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death.
MLA
Ko, Huey-Jiun, et al. “BMX, a Specific HDAC8 Inhibitor, with TMZ for Advanced CRC Therapy: A Novel Synergic Effect to Elicit P53-, β-Catenin- and MGMT-Dependent Apoptotic Cell Death.” Cell Communication & Signaling, vol. 20, no. 1, Dec. 2022, pp. 1–19. EBSCOhost, https://doi.org/10.1186/s12964-022-01007-x.
APA
Ko, H.-J., Chiou, S.-J., Tsai, C.-Y., Loh, J.-K., Lin, X.-Y., Tran, T.-H., Hou, C.-C., Cheng, T.-S., Lai, J.-M., Chang, P. M.-H., Wang, F.-S., Su, C.-L., Huang, C.-Y. F., & Hong, Y.-R. (2022). BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death. Cell Communication & Signaling, 20(1), 1–19. https://doi.org/10.1186/s12964-022-01007-x
Chicago
Ko, Huey-Jiun, Shean-Jaw Chiou, Cheng-Yu Tsai, Joon-Khim Loh, Xin-Yi Lin, Thu-Ha Tran, Chia-Chung Hou, et al. 2022. “BMX, a Specific HDAC8 Inhibitor, with TMZ for Advanced CRC Therapy: A Novel Synergic Effect to Elicit P53-, β-Catenin- and MGMT-Dependent Apoptotic Cell Death.” Cell Communication & Signaling 20 (1): 1–19. doi:10.1186/s12964-022-01007-x.